Roche Diagnostics Canada has received approval from Health Canada for the cobas EGFR Mutation test v2. This real-time polymerase chain reaction test identifies 42 mutations in exons 18–21 of the epidermal growth factor receptor (EGFR) gene, which is the largest number of EGFR mutations detected by an in vitro diagnostic on the market, according to Roche. Healthcare providers will be able to use the test to identify non-small cell lung cancer patients who have a T790M mutation, exon 19 deletions, or L858R mutations and are most likely to benefit from therapy with an EGFR tyrosine kinase inhibitor. Designed to run on the cobas 4800 system, v2.1 or higher, the cobas EGFR Mutation test v2 enables testing of either tissue or plasma specimens with one kit, and allows labs to mix-batch tissue and plasma on the same plate. Additionally, Roche has developed an accompanying cell-free DNA sample preparation kit that is optimized for extracting DNA from plasma.